What attracted you to Ori?

I feel so inspired by Ori’s mission: to make life-saving therapies accessible to everyone.

When I first joined Ori as an intern, I was instantly impressed by the team’s motivation, passion, and their innovative team spirit, which allows me to apply everything that I have learned and the skills that I have previously gained, while simultaneously learning something new every day.

What is your role at Ori?

I currently work as an Associate Scientist at Ori. I am involved in supporting the ongoing laboratory work which requires both the testing and the development of Ori’s novel technology. In parallel, I am working with the data team to develop a way of recording and storing data that facilitates easier data analysis, in addition to testing different data platforms.

Can you tell us a little bit about your background, prior to Ori?

This year, I graduated from UCL with a first-class honours MEng degree in Biochemical Engineering. I was trained in bioreactor design, upstream and downstream processes, and design of the overall vein-to-vein production of novel therapies.

Outside of university, I have worked in different research institutes and laboratories in order to develop my practical skills. I helped develop a platform for testing the effect of novel therapies on microtumors and the development of a fast method for detecting SARS-CoV-2.

What drew you to cell and gene therapy?

My interest in CGT developed during my time at UCL, where I realized that these therapies are the future of medicine.

I’m really interested in how to make CGTs more cost-effective, accessible to all patients and potentially used as a first-line treatment through automated manufacturing.

What do you think the future of digital healthcare looks like?

I believe the process of digitalization and automation is going to facilitate the discovery, development and manufacture of novel therapies while reducing the overall therapeutic cost.

Also, I believe the digitalization of healthcare will help save lives – as suitable treatments will be readily available for patients globally, once novel therapy manufacture starts following a decentralized model.